Spire Wealth Management Boosts Investment in iShares Biotechnology ETF

On February 6, 2025, it was reported that Spire Wealth Management has significantly increased its investment in the iShares Biotechnology ETF (NASDAQ:IBB). In its latest filing with the Securities and Exchange Commission (SEC), the firm disclosed that it raised its position by 65.9% during the fourth quarter of the previous year. Following this purchase, Spire Wealth Management now owns a total of 4,274 shares of the ETF, with the new acquisition of 1,698 shares playing a key role in this growth. The total value of Spire Wealth Management's holdings in iShares Biotechnology ETF stands at approximately $565,000 as reported in the SEC filing.

In addition to Spire Wealth Management, several other institutional investors and hedge funds have also adjusted their stakes in the iShares Biotechnology ETF. For instance, SPC Financial Inc. increased its holdings by 2.4% during the third quarter, bringing its total to 3,265 shares valued at $475,000 after buying 75 additional shares. Similarly, Werba Rubin Papier Wealth Management boosted its stake by 2.7% to own 2,918 shares worth $425,000 after acquiring 76 more shares. Chicago Partners Investment Group LLC also increased its holdings by 2.5% in the fourth quarter, now owning 3,783 shares valued at $510,000 after purchasing 94 shares. Furthermore, Capital Investment Advisors LLC raised its position by 1.0%, owning 10,449 shares valued at $1,381,000, and Magnus Financial Group LLC lifted its holdings by 0.8% to own 12,967 shares worth $1,714,000 with an additional purchase of 104 shares. Notably, approximately 62.45% of the iShares Biotechnology ETF shares are held by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Overview

The iShares Biotechnology ETF opened at $142.33 on a Thursday in February. The ETF has a fifty-day simple moving average of $136.31 and a 200-day simple moving average of $141.47. In the past year, its shares have experienced a low of $123.60 and a high of $150.57, highlighting the volatility and trading activity within the biotechnology sector.

Dividend Announcement

Recently, iShares Biotechnology ETF also announced a dividend which was paid out on December 20th, following its record date on December 17th. Shareholders received a dividend of $0.0624 per share, marking the company’s ongoing commitment to returning value to its investors.

About iShares Biotechnology ETF

The iShares Nasdaq Biotechnology ETF, formerly known as the iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund designed to track the performance of the NASDAQ Biotechnology Index. This index comprises securities from companies classified within the biotechnology and pharmaceutical sectors listed on the NASDAQ, thus offering investors a focused exposure to the biotechnology industry.

investment, biotechnology, ETF